Glide™ Technology | Data and Clinical Experience
Studies using the needle-less Glide technology have demonstrated that:
- Minimal skin response is seen following the administration of drugs to skin with a prototype delivery system
- 100% of the drug (compared to a subcutaneous needle and syringe injection) is seen in the systemic circulation following the administration of a solid dose insulin formulation
- Excellent dose response is observed with increasing drug doses
- Rapid delivery of the drug to the systemic circulation is achieved minutes after the administration - this speed of onset can be modified, as desired, with a sustained release / controlled release formulation
- Bioequivalence has been demonstrated enabling the development of ‘generic’ drug products
Laboratory data have been generated with a number of drugs ranging from small molecules (e.g. sumatriptan) through to proteins (e.g. insulin and erythropoietin).
Glide Pharma has completed a clinical trial that demonstrated the safety and tolerance of the Glide technology versus traditional needle and syringe administration. The study compared the sensation felt by volunteers using the different drug delivery systems.
The trial showed:
- No difference in sensation felt by the volunteers with the needle-free Glide system compared to the 27-gauge needle and syringe injection (one of the smallest standard needle sizes commonly available).
- No bruising and / or bleeding at any of the Glide injection sites compared to 12.5% of the needle and syringe injection sites
- Glide was preferred due to the speed of injection compared to needle and syringe, although the sensation was similar
The study design was a single centre, single-blind, randomized, crossover, Phase I study in human volunteers.
